# Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

Source: https://onco.cc/trials/nct04410133/  
OnCo record `nct04410133` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Fluciclovine F-18 in Brain metastases, run by Blue Earth Diagnostics, completed.

## Summary

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases is a phase 3 interventional study registered as NCT04410133 by Blue Earth Diagnostics, with 151 participants recorded, started 2020-10-26 and reaching its primary completion in 2023-06-05. Interventions recorded: 18F fluciclovine. Conditions recorded: Brain Metastases.

Linked to the drug Fluciclovine F-18 because the registry names it among its interventions and Brain metastases among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04410133
- Phase: 3
- Setting: An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy
- Sponsor: Blue Earth Diagnostics
- Enrolled: 151

## Sources

- ClinicalTrials.gov NCT04410133: https://clinicaltrials.gov/study/NCT04410133

## Connected records

- cancers: [Brain metastases (secondary brain tumours)](https://onco.cc/cancers/secondary-brain-tumours/)
- drugs: [Fluciclovine F-18](https://onco.cc/drugs/fluciclovine-f18/)
- companies: [Blue Earth Diagnostics (Bracco)](https://onco.cc/companies/blue-earth-diagnostics/)

---
JSON: https://onco.cc/api/v1/entities/nct04410133.json